Algia Pharma

Algia Pharma is a clinical-stage biopharmaceutical company focused on the development of novel, non-opioid therapies for chronic pain management. The company's lead candidate, ALG-001, is a proprietary prodrug of R-baclofen, the active isomer of the GABA-B receptor agonist baclofen. ALG-001 is designed to improve the pharmacokinetic profile and therapeutic index of baclofen for treating neuropathic pain conditions such as post-herpetic neuralgia and diabetic peripheral neuropathy. By leveraging its expertise in pain pathways, Algia Pharma seeks to provide safer and more effective alternatives to current standard-of-care treatments and opioids.